DDInter1782 DDInter915
Tetracosactide (also known as Cosyntropin) is a synthetic peptide that is identical to the 24-amino acid segment (sequence: SYSMEHFRWGKPVGKKRRPVKVYP) at the N-terminal of adrenocorticotropic hormone. ACTH (1-24), a segment similar in all species, contains the biological activity that stimulates production of corticosteroids in the adrenal cortex. Tetracosactide exhibits the same activity as natural ACTH with regard to all its biological activities. The complex results in a product whose absorption in man is effected over a longer period of time as compared to corticotropin. Therefore, therapy may be maintained with less frequent administration.
Indacaterol is a novel, ultra-long-acting, rapid onset β(2)-adrenoceptor agonist developed for Novartis for the once-daily management of asthma and chronic obstructive pulmonary disease. It was approved by the European Medicines Agency (EMA) on 30 November 2009 and by the FDA on 1 July 2011. It is marketed in Europe as Onbrez and in America as Arcapta Neohaler. Indacaterol is provided as its maleate salt form. Indacaterol is also a chiral molecule but only the pure R-enantiomer is dispensed.
Tetracosactide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Salbutamol
Salbutamol {u} (Compound) treats {v} (Disease) asthma
asthma {u} (Disease) is treated by {v} (Compound) Indacaterol
Tetracosactide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Theophylline
Theophylline {u} (Compound) treats {v} (Disease) asthma
asthma {u} (Disease) is treated by {v} (Compound) Indacaterol
Tetracosactide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Salbutamol
Salbutamol {u} (Compound) binds {v} (Gene) ADRB1
ADRB1 {u} (Gene) is bound by {v} (Compound) Indacaterol
Tetracosactide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Theophylline
Theophylline {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Indacaterol
Tetracosactide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Theophylline
Theophylline {u} (Compound) causes {v} (Side Effect) Atrial fibrillation
Atrial fibrillation {u} (Side Effect) is caused by {v} (Compound) Indacaterol
Tetracosactide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Salbutamol
Salbutamol {u} (Compound) is included by {v} (Pharmacologic Class) Adrenergic beta2-Agonists
Adrenergic beta2-Agonists {u} (Pharmacologic Class) includes {v} (Compound) Indacaterol
Tetracosactide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Salbutamol
Salbutamol {u} (Compound) causes {v} (Side Effect) Cardiac disorder
Cardiac disorder {u} (Side Effect) is caused by {v} (Compound) Indacaterol
Tetracosactide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Penbutolol
Penbutolol {u} (Compound) binds {v} (Gene) ADRB1
ADRB1 {u} (Gene) is bound by {v} (Compound) Indacaterol
Tetracosactide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Penbutolol
Penbutolol {u} (Compound) causes {v} (Side Effect) Headache
Headache {u} (Side Effect) is caused by {v} (Compound) Indacaterol
Tetracosactide {u} may lead to a major life threatening interaction when taken with {v} Bupropion
Bupropion {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Indacaterol
Tetracosactide may cause a minor interaction that can limit clinical effects when taken with Salbutamol and Salbutamol (Compound) treats asthma (Disease) and asthma (Disease) is treated by Indacaterol (Compound)
Tetracosactide may cause a moderate interaction that could exacerbate diseases when taken with Theophylline and Theophylline (Compound) treats asthma (Disease) and asthma (Disease) is treated by Indacaterol (Compound)
Tetracosactide may cause a minor interaction that can limit clinical effects when taken with Salbutamol and Salbutamol (Compound) binds ADRB1 (Gene) and ADRB1 (Gene) is bound by Indacaterol (Compound)
Tetracosactide may cause a moderate interaction that could exacerbate diseases when taken with Theophylline and Theophylline (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Indacaterol (Compound)
Tetracosactide may cause a moderate interaction that could exacerbate diseases when taken with Theophylline and Theophylline (Compound) causes Atrial fibrillation (Side Effect) and Atrial fibrillation (Side Effect) is caused by Indacaterol (Compound)
Tetracosactide may cause a minor interaction that can limit clinical effects when taken with Salbutamol and Salbutamol (Compound) is included by Adrenergic beta2-Agonists (Pharmacologic Class) and Adrenergic beta2-Agonists (Pharmacologic Class) includes Indacaterol (Compound)
Tetracosactide may cause a minor interaction that can limit clinical effects when taken with Salbutamol and Salbutamol (Compound) causes Cardiac disorder (Side Effect) and Cardiac disorder (Side Effect) is caused by Indacaterol (Compound)
Tetracosactide may cause a moderate interaction that could exacerbate diseases when taken with Penbutolol and Penbutolol (Compound) binds ADRB1 (Gene) and ADRB1 (Gene) is bound by Indacaterol (Compound)
Tetracosactide may cause a moderate interaction that could exacerbate diseases when taken with Penbutolol and Penbutolol (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Indacaterol (Compound)
Tetracosactide may lead to a major life threatening interaction when taken with Bupropion and Bupropion (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Indacaterol (Compound)